-

10:18:25 PM

VCEL Stock News

VCEL - Vericel Corp

09/28/23 8:30 AM

Nasdaq : VCEL

clinical trial

Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared to Gel Vehicle and standard of care Results demonstrate that NexoBrid is safe and well-tolerated

RHEA-AI

neutral

09/20/23 4:30 PM

Nasdaq : VCEL

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid launch significantly expands the total addressable market for Vericel Burn Care CAMBRIDGE, Mass., Sept.

RHEA-AI

neutral

09/06/23 8:30 AM

Nasdaq : VCEL

conferences

Vericel to Present at the Morgan Stanley Global Healthcare Conference

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21 st

RHEA-AI

neutral

08/02/23 7:55 AM

Nasdaq : VCEL

earnings

Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year MACI Revenue Growth of 27% to $36.3 Million Epicel Revenue Growth of 17% to $9.6 Million Full-Year 2023 Revenue Guidance Raised to $190-197 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE,

RHEA-AI

neutral

07/20/23 8:30 AM

Nasdaq : VCEL

conferencesearnings

Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023. Vericel’s

RHEA-AI

neutral

05/10/23 7:55 AM

Nasdaq : VCEL

earnings

Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Vericel Corporation (NASDAQ:VCEL), a leader in

RHEA-AI

neutral

05/02/23 9:00 AM

Nasdaq : VCEL, SGTX

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. Dr. Wotton fills the role

RHEA-AI

very positive

04/26/23 8:30 AM

Nasdaq : VCEL

conferencesearnings

Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s

RHEA-AI

neutral

02/28/23 8:30 AM

Nasdaq : VCEL

conferences

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The

RHEA-AI

neutral

02/23/23 7:55 AM

Nasdaq : VCEL

earnings

Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million, with MACI Revenue of $132 Million Full-Year 2023 Total Revenue Guidance of $180 to $188 Million, with MACI Revenue of $152 to $156 Million Conference Call Today at 8:30am

RHEA-AI

positive

1 2 3 4 5 6 7 Next

VCEL Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitehttps://vcel.com/
Security nameVericel Corp
SectorManufacturing
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
CountryUS

About Vericel Corp

about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea